-
CNGB Virogin’s VG161 On Track for Breakthrough Designation in China for Advanced Liver Cancer
•
BEIJING—CNGB Virogin, a joint venture between Virogin Biotech and China National Biotec Group, is poised to secure a breakthrough therapy designation (BTD) from China’s National Medical Products Administration (NMPA) for its innovative drug VG161. The targeted indication for this recombinant human IL12/15-PDL1B herpes simplex type I oncolytic virus injection is…
-
China’s Healthcare Statistics Show Improvements in Life Expectancy and Access to Medical Services
•
BEIJING—The National Health Commission (NHC) of China has published the “China’s Healthcare Statistical Communique 2023,” highlighting significant strides in public health outcomes and healthcare resource allocation. In 2023, the life expectancy of Chinese residents reached a historic high of 78.6 years, while both the maternal mortality rate and infant mortality…
-
Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1
•
SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first half of 2024, with revenues reaching RMB 20.53 billion, marking an 11.12% year-on-year increase. The net profit saw a robust rise, climbing to RMB 7.56 billion, which is a 17.37% increase. Despite a 7.59% YOY…
-
Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight
•
HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for the first half of 2024, reflecting a 46.0% year-on-year increase in revenues, which reached RMB 102.7 million. This growth is primarily attributed to the strong performance of its flagship hypoglycemic agent, HuaTangNing (dorzagliatin tablets). Despite…
-
American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data
•
WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered that over a thousand patents registered by Chinese inventors have received financial support from the US Defense Department, NASA, and other federal agencies. The analysis, which reviewed data from the USPTO dating back to 2010,…
-
GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer
•
SUZHOU—GeneQuantum, a leading player in the biotech industry known for its cutting-edge enzymatic site-specific conjugation technologies, has announced the appointment of Dr. Lingyu Zhu as its Chief Business Strategy and Development Officer. Dr. Zhu’s name surfaced in the recent 8th Asia-Pacific Biopharma Partnership Summit’s list of pharmaceutical business development leaders,…
-
Jiangxi Healthcare Security Administration Launches Initiative to Widen Drug Availability
•
JIANGXI—In a strategic move to enhance drug accessibility, the Healthcare Security Administration (HSA) bureau of Jiangxi province has initiated a province-wide campaign known as the “Three Entries,” aiming to make centrally procured drugs available in retail pharmacies, private medical institutions, and village clinics, including community health service centers and stations.…
-
China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation
•
BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has suffered a significant setback in China. According to the latest information, three decisions from China’s Supreme Court in May 2024 have upheld the cancellation of Sanofi’s formulation patents for Aubagio tablets, as requested by an…
